Print this page Email this page
Users Online: 155
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Contacts Login 


 
 Table of Contents  
LETTER TO EDITOR
Year : 2021  |  Volume : 35  |  Issue : 1  |  Page : 46

Safety of COVID-19 vaccine in the patient with history of drug allergy: An issue to be monitored


1 Private Academic Consultant, Bangkok, Thailand
2 Department of Community Medicine, Dr DY Patil University, Pune, Maharashtra, India

Date of Submission25-Mar-2021
Date of Acceptance28-Jun-2021
Date of Web Publication04-Aug-2021

Correspondence Address:
Pathum Sookaromdee
Private Academic Consultant, Bangkok
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jms.jms_55_21

Rights and Permissions

How to cite this article:
Sookaromdee P, Wiwanitkit V. Safety of COVID-19 vaccine in the patient with history of drug allergy: An issue to be monitored. J Med Soc 2021;35:46

How to cite this URL:
Sookaromdee P, Wiwanitkit V. Safety of COVID-19 vaccine in the patient with history of drug allergy: An issue to be monitored. J Med Soc [serial online] 2021 [cited 2021 Oct 26];35:46. Available from: https://www.jmedsoc.org/text.asp?2021/35/1/46/323163



Sir,

COVID-19 vaccine is the newest vaccine for COVID-19 containment. At present, more than one million doses of vaccines have already been administered in many countries. There are already some reports on the postvaccination adverse effects of the new vaccines. Many reports are from the US and Europe.[1],[2] In a recent publication in British Medical Journal (BMJ),[3] it is recommended that the allergy test might be applied for risk assessment among people who report allergies. However, there is still a simple question that we should better not vaccinate anyone who reports a history of allergy or not.

Here, we would like to share the latest public data from the first public report (March 2021) on COVID-19 vaccination in Indochina. In this setting, a non-mRNA vaccine, inactivated vaccine, is used and the preliminary report by local CDC (https://covid-19.kapook.com/view238376.html and https://gnews.apps.go.th/news?news=79505) noted that there were 7,262 vaccinnees within the first 3 – day period and the severe adverse effect was already reported in 1 case, giving incidence rate equal to 0.0138 % or 138 per 1,000,000. The indexed case who developed severe adverse effect had a history of penicillin allergy but still received COVID-19 vaccine. Although some scientists might propose that non-mRNA COVID-19 vaccine is safer than RNA COVID-19 vaccine, the data from the preliminary report are discordant. Comparing the data to the previous report on mRNA COVID-19 vaccine (anaphylaxis rate: 11.1/1,000,000[1]), the observed severe adverse effect is significantly higher. It might assume that any person with history of any allergy (drug, food, or others) should not be vaccinated, regardless of type of vaccine, until there are more evidences to confirm for safety. The basic principle of “first do no harm” should be applied for decision-making in vaccination for a case with history of allergy.[4]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
CDC COVID-19 Response Team, Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 Vaccine-United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep 2021;70:46-51.  Back to cited text no. 1
    
2.
Banerji A, Wickner PG, Saff R, Stone CA Jr., Robinson LB, Long AA, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: Current evidence and suggested approach. J Allergy Clin Immunol Pract 2021;9:1423-37.  Back to cited text no. 2
    
3.
Glover RE, Urquhart R, Lukawska J, Blumenthal KG. Vaccinating against covid-19 in people who report allergies. BMJ 2021;372:n120.  Back to cited text no. 3
    
4.
Wiwanitkit V. Re: Vaccinating Against Covid-19 in People Who Report Allergies. Available from: https://www.bmj.com/content/372/bmj.n120/rr-2. [Last accessed on 2021 Jul 10].  Back to cited text no. 4
    




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
References

 Article Access Statistics
    Viewed250    
    Printed4    
    Emailed0    
    PDF Downloaded47    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]